28.31
Schlusskurs vom Vortag:
$28.53
Offen:
$28.69
24-Stunden-Volumen:
548.87K
Relative Volume:
0.87
Marktkapitalisierung:
$1.41B
Einnahmen:
$534.53M
Nettoeinkommen (Verlust:
$-11.45M
KGV:
-117.42
EPS:
-0.2411
Netto-Cashflow:
$48.28M
1W Leistung:
-4.13%
1M Leistung:
-9.44%
6M Leistung:
-17.29%
1J Leistung:
-15.14%
Atricure Inc Stock (ATRC) Company Profile
Firmenname
Atricure Inc
Sektor
Telefon
513-755-4100
Adresse
7555 INNOVATION WAY, MASON, OH
Compare ATRC vs ISRG, BDX, ALC, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
ATRC
Atricure Inc
|
28.31 | 1.42B | 534.53M | -11.45M | 48.28M | -0.2411 |
|
ISRG
Intuitive Surgical Inc
|
464.45 | 163.73B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
156.34 | 44.73B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
75.51 | 36.73B | 10.40B | 980.00M | 1.61B | 1.9749 |
|
MDLN
Medline Inc
|
44.00 | 36.12B | 28.43B | 1.16B | 1.26B | 1.4457 |
|
RMD
Resmed Inc
|
222.85 | 32.70B | 5.40B | 1.49B | 1.78B | 10.12 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2026-02-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-12-17 | Fortgesetzt | JP Morgan | Overweight |
| 2024-04-23 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-23 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-09-29 | Eingeleitet | UBS | Buy |
| 2021-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-12-18 | Bestätigt | Needham | Buy |
| 2020-11-06 | Bestätigt | Needham | Buy |
| 2020-04-07 | Eingeleitet | Oppenheimer | Outperform |
| 2020-02-06 | Eingeleitet | BTIG Research | Buy |
| 2020-01-24 | Bestätigt | Needham | Buy |
| 2019-08-13 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-04-12 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-04 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Stifel | Buy |
| 2018-06-18 | Bestätigt | Needham | Buy |
| 2018-04-27 | Bestätigt | Needham | Buy |
| 2018-01-16 | Bestätigt | Needham | Buy |
| 2017-11-02 | Bestätigt | Needham | Buy |
| 2017-07-28 | Bestätigt | Needham | Buy |
| 2017-05-30 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-06-30 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2015-10-28 | Bestätigt | Needham | Buy |
| 2015-10-06 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-06 | Bestätigt | Needham | Buy |
Alle ansehen
Atricure Inc Aktie (ATRC) Neueste Nachrichten
Freedom Capital Markets initiates Articure stock with buy rating - investing.com
ATRC Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Valuation Update: What are AtriCure Incs recent SEC filings showingQuarterly Market Review & Stock Market Timing Techniques - baoquankhu1.vn
AtriCure, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges - marketsmojo.com
AtriCure Inc (ATRC) Stock Price Quote Today & Current Price Chart - Capital.com
AtriCure Inc (ATRC) Stock Price Quote Today & Current Price Chart | Capital.com Australia - Capital.com
Resistance Check: Whats the fair value of AtriCure Inc stock2026 Setups & Technical Pattern Alert System - baoquankhu1.vn
AtriCure (NASDAQ:ATRC) Hits New 1-Year LowHere's Why - MarketBeat
AtriCure stock hits 52-week low at $28.25 amid market fluctuations - investing.com
Risk Check: Is AtriCure Inc a top pick in the sector2026 Final Week & Consistent Growth Equity Picks - baoquankhu1.vn
Technical Reactions to ATRC Trends in Macro Strategies - news.stocktradersdaily.com
AtriCure (NASDAQ:ATRC) Rating Lowered to "Buy" at Wall Street Zen - MarketBeat
Projecting the Global Cardiac Ablation Devices Market Size to Expand at a 13.25% CAGR Through 2032, DelveInsight Analysis - Barchart.com
Vanguard disaggregates holdings; AtriCure (NASDAQ: ATRC) shows 0 shares - Stock Titan
Market Outlook: What are the analyst revisions for SMTCIs AtriCure Inc stock a good investment in YEARTake Profit & Safe Capital Investment Plans - baoquankhu1.vn
Trend Report: Is AtriCure Inc in accumulation or distribution phase2026 Market Sentiment & Weekly Return Optimization Plans - baoquankhu1.vn
AtriCure, Inc. Experiences Revision in Stock Evaluation Amidst Market Challenges - marketsmojo.com
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching? - AOL.com
MACD Signal: Should value investors consider AtriCure Inc2026 Retail Activity & Weekly High Return Forecasts - baoquankhu1.vn
DAFNA Capital Management Sells Axogen Shares in 2025News and Statistics - indexbox.io
ATRC Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Market Wrap: Is now the right time to enter AtriCure IncPortfolio Return Report & Accurate Intraday Trading Signals - baoquankhu1.vn
AtriCure Chief Scientific Officer Stock SaleMarch 2026 Transaction DetailsNews and Statistics - IndexBox
AtriCure unveils case-based training to build Afib program skills - Traders Union
AtriCure Stock Forms Death Cross, Signaling Bearish Trend Ahead - marketsmojo.com
Aug Patterns: Is AtriCure Inc undervalued by DCF analysisMarket Weekly Review & Weekly High Momentum Picks - baoquankhu1.vn
Growth Value: Is AtriCure Inc stock trending bullish2026 Selloffs & Real-Time Stock Movement Alerts - baoquankhu1.vn
Ablation Devices Market to Reach USD 15.34 Billion by 2034, Growing at a CAGR of 8.38% Driven by Rising Chronic Disease Burden and Advancements in Minimally Invasive Technologies | DelveInsight - Barchart.com
Investor Mood: Should I hold or sell ABRPRF now2026 Volume Leaders & High Accuracy Investment Signals - baoquankhu1.vn
Trading the Move, Not the Narrative: (ATRC) Edition - Stock Traders Daily
Insider Sell: Vinayak Doraiswamy Sells 5,000 Shares of AtriCure Inc (ATRC) - GuruFocus
Growth Value: Why is AtriCure Inc stock going downIndex Update & Growth Focused Investment Plans - baoquankhu1.vn
AtriCure (NASDAQ:ATRC) Insider Vinayak Doraiswamy Sells 5,000 Shares - MarketBeat
AtriCure CSO Doraiswamy sells $149k in stock - Investing.com Nigeria
AtriCure CSO Doraiswamy sells $149k in stock By Investing.com - Investing.com Australia
AtriCure (ATRC) Chief Scientific Officer sells 5,000 shares at $29.83 - Stock Titan
First Light Asset Management LLC Sells 124,808 Shares of AtriCure, Inc. $ATRC - MarketBeat
Kennedy Capital Management LLC Boosts Stock Holdings in AtriCure, Inc. $ATRC - MarketBeat
ATRC (NASDAQ: ATRC) files Form 144 reporting proposed sale of award shares - Stock Titan
Director at AtriCure (NASDAQ: ATRC) exercises 10,000 stock options - Stock Titan
Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (ATRC), Q32 Bio (QTTB) and Shoulder Innovations, Inc. (SI) - The Globe and Mail
AtriCure CFO Sees 12%-14% Organic Growth in 2026 as Pain Management Adoption Accelerates - Yahoo Finance
AtriCure at The Citizens Life Sciences Conference: Strategic Growth Outlook By Investing.com - Investing.com Canada
AtriCure, Inc. (NASDAQ:ATRC) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
ATRC Technical Analysis & ETF Price Forecast - Intellectia AI
AtriCure (ATRC) CEO reports family stock gifts in Form 4 - Stock Titan
Citigroup Inc. Purchases 36,839 Shares of AtriCure, Inc. $ATRC - MarketBeat
Moving Averages: Does AtriCure Inc have declining or rising EPS2026 Winners & Losers & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Aug Opening: Is AtriCure Inc a cyclical or defensive stockEarnings Overview Summary & Daily Stock Trend Reports - baoquankhu1.vn
AtriCure price target raised to $48 from $42 at JPMorgan - MSN
Energy Moves: Is AtriCure Inc stock trending bullish2025 Fundamental Recap & Community Verified Trade Alerts - baoquankhu1.vn
Finanzdaten der Atricure Inc-Aktie (ATRC)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):